In The News: School of Integrated Health Sciences
Alzheimer’s disease is a progressive neurological disorder that leads to brain atrophy and death of its cells. It is the most common cause of dementia. It leads to a persistent decrease in the ability to think, and in behavioral and social skills; This limits a person’s ability to live independently.
According to a new study published this month in the Journal of Affective Disorders, vegetarians experienced depressive episodes twice as often as those who ate meat.
Drugmakers Biogen and Eisai say their experimental drug lecanemab slowed the progress of Alzheimer’s disease in a large human study the companies did.
As far as UNLV students go, she was older, in her 30s. McKenzie Mayor remembers sensing despair. The woman likely had lost her job, money was tight, Mayor thought.
An experimental Alzheimer's drug made by Eisai Co Ltd (4523.T) and Biogen (BIIB.O) slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, they said on Tuesday, potentially a rare win in a field littered with failed drugs.
An experimental Alzheimer's drug made by Eisai Co Ltd and Biogen slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, they said on Tuesday, potentially a rare win in a field littered with failed drugs.
There are more than two million people living with an amputation in the United States, with about 400 being added daily. For many of them, prostheses or artificial limbs are a part of their lives, and they need to relearn how their bodies move with their new limbs all over again.
There are more than two million people living with an amputation in the United States, with about 400 being added daily. For many of them, prostheses or artificial limbs are a part of their lives, and they need to relearn how their bodies move with their new limbs all over again.
Running can lead to a lot of injuries. So how can a runner remain fit while they heal?
NervGen is developing a novel drug candidate that could revolutionise treatment for conditions associated with central nervous system damage, including Alzheimer’s disease.
Right now, Nevada has the third-fastest rate of growth for Alzheimer’s disease. Between now and 2025, the number of Nevadans with dementia is expected to grow almost 31% from 49,000 to 64,000.
The test, which measures β-amyloid in cerebrospinal fluid, received FDA de novo classification, making it the first IVD available for detection of brain amyloid plaques.